Merck to Acquire Afferent for up to $1.25 billion

Read More

Congratulations to Our 2016 NEVY Award Winners Editas Medicine and Decibel Therapeutics

Read More

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology

Read More

Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy

Read More

CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates

Read More

Nature Biotechnology highlights Neon Therapeutics in its list of academic spinouts of 2015

Read More

Congratulations to Voyager Therapeutics on being named one of The Boston Business Journal's 2016 Best Places to Work

Read More
pliant launch

Pliant Therapeutics launches with $45 million to develop breakthrough treatments for fibrotic diseases

Read More

Take a look at what we’ve been up to for the past 8+ years

Watch the Video

Revolution Medicines Featured in Chemical & Engineering News’ List of the Top Startups to Watch of 2015

Read More

Check out Nurix and Afferent Featured in Forbes’ Hottest Startups of 2015

Read More

Partner Profile: Neil Exter

Read More

Decibel Therapeutics Launches with $52 million to Discover New Medicines to Protect, Repair and Restore Hearing

Read More

Congrats to partner Mark Levin for being recognized on BBJ's Power 50 list

Read More

Immuno-oncology Company Neon Therapeutics Launches With $55M Series A Financing

Read More

Sign up for weekly portfolio company news alerts here
 

Read More

Andrew Stricos, who has Huntington’s disease, and his wife tell their story at a luncheon hosted by Third Rock

Watch the Video

Transforming Healthcare

39

Portfolio Companies
With More Than $1.3 Billion
Under Management

45

Clinical Studies
Underway Within Our Portfolio

60

Diseases
Being Targeted By
Our Companies

10  

of thousands

Patients Impacted
By Portfolio Company Products
and Clinical Trials